IRF8 and neoplasm: In the TME, interferon regulatory factor 8 (IRF8)-dependent CD103+ cDC1 (CD141+ cDC1 in human) are the only APCs that can cross present tumor rejection Ags for activation of specific CTLs 23, which are sparsely distributed and frequently threatened by the hostile immunosuppressive environment 188.